Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 5/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.60 |
| ▸ | MEN1 | O00255 | 4/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.60 |
| ▸ | LMNA | P02545 | 3/20 | 0.60 |
| ▸ | HTT | P42858 | 2/20 | 0.60 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.60 |
| ▸ | RAB9A | P51151 | 5/20 | 0.57 |
| ▸ | TP53 | P04637 | 1/20 | 0.56 |
| ▸ | TSHR | P16473 | 1/20 | 0.56 |
| ▸ | CA2 | P00918 | 3/20 | 0.55 |
| ▸ | CNR1 | P21554 | 1/20 | 0.55 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.53 |
| ▸ | NTRK1 | P04629 | 3/20 | 0.52 |
| ▸ | CA12 | O43570 | 1/20 | 0.51 |
| ▸ | CA1 | P00915 | 1/20 | 0.51 |
| ▸ | CA9 | Q16790 | 1/20 | 0.51 |
| ▸ | GRM4 | Q14833 | 2/20 | 0.51 |
| ▸ | KCNJ5 | P48544 | 1/20 | 0.51 |
| ▸ | KCNJ3 | P48549 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4106124 | 0.89 | CA2 (0.68) | MAPTSMN1; SMN2MEN1KMT2ALMNA | |
| SCHEMBL4113827 | 0.87 | MAPT (0.75) | MAPTSMN1; SMN2MEN1KMT2ALMNA | |
| SCHEMBL4124118 | 0.87 | KMT2A (0.69) | MAPTSMN1; SMN2MEN1KMT2ALMNA | |
| SCHEMBL4106286 | 0.87 | MAPT (0.65) | MAPTSMN1; SMN2MEN1KMT2ALMNA | |
| SCHEMBL4104472 | 0.86 | MAPT (0.67) | MAPTSMN1; SMN2MEN1KMT2ALMNA | |
| SCHEMBL4125153 | 0.86 | MAPT (0.67) | MAPTSMN1; SMN2MEN1KMT2ALMNA | |
| SCHEMBL4117916 | 0.86 | TP53 (0.76) | MAPTSMN1; SMN2MEN1KMT2ALMNA | |
| SCHEMBL4117939 | 0.86 | CNR1 (0.64) | MAPTSMN1; SMN2MEN1KMT2ALMNA | |
| SCHEMBL4117429 | 0.86 | MAPT (0.62) | MAPTSMN1; SMN2MEN1KMT2ALMNA | |
| SCHEMBL4105961 | 0.86 | SMN1; SMN2 (0.65) | MAPTSMN1; SMN2MEN1KMT2ALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090239841-A1 | Diaryl Ureas as CB1 Antagonists | NEUROGEN CORPORATION | 2009-09-24 | — | — | US | disclosed |
| US-20090239841-A1 | Diaryl Ureas as CB1 Antagonists | NEUROGEN CORPORATION | 2009-09-24 | — | — | US | disclosed |
| US-20090239841-A1 | Diaryl Ureas as CB1 Antagonists | NEUROGEN CORPORATION | 2009-09-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090239841-A1 | Diaryl Ureas as CB1 Antagonists | CNR1, CNR2, OPRL1 | MAPT 1654/4885SMN1; SMN2 4056/4885MEN1 3273/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.